GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

AUTL · Jun 30, 2026

Autolus Therapeutics plc. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001730463-26-000123General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

2.00% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-54.87% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

118.37% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

73.17% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

55.20% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-95.95% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

61.06% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

10.06% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History7 statesHistory building

Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20250/7 normalizedLevel 3 Dec 31, 20250/8 normalizedLevel 3 Mar 31, 20260/8 normalizedLevel 3 Jun 30, 20260/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Decreased

Previous: 10.25%
Current: 2.00%
Delta: -8.25%

Cash Generation Increased

Previous: -249.13%
Current: -54.87%
Delta: 194.26%

Growth Decreased

Previous: 191.89%
Current: 118.37%
Delta: -73.53%

Inventory Pressure Decreased

Previous: 126.76%
Current: 73.17%
Delta: -53.59%

Margin Increased

Previous: 6.29%
Current: 55.20%
Delta: 48.91%

Profitability Increased

Previous: -226.99%
Current: -95.95%
Delta: 131.04%

R And D Intensity Decreased

Previous: 80.90%
Current: 61.06%
Delta: -19.84%

Sbc Intensity Decreased

Previous: 13.60%
Current: 10.06%
Delta: -3.54%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Compared To · Biological Products, (No Diagnostic Substances) peers →Transitioned To · AUTL Fundamental State →Transitioned To · AUTL CAPEX_INTENSITY_DECREASED →Transitioned To · AUTL CASH_GENERATION_INCREASED →Transitioned To · AUTL GROWTH_DECREASED →Transitioned To · AUTL INVENTORY_PRESSURE_DECREASED →Transitioned To · AUTL MARGIN_INCREASED →Transitioned To · AUTL PROFITABILITY_INCREASED →Transitioned To · AUTL R_AND_D_INTENSITY_DECREASED →Transitioned To · AUTL SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.